TNF and psoriasis: Overall, 82 patients received biologic therapy with either anti-TNFa, anti-IL-12/23, or anti-IL-17 agents and 52 patients received only topical or light therapy (control group), while most of them had low cardiovascular risk by traditional risk scores and moderate–severe psoriasis.